Epigenetic regulation of cutaneous T-cell lymphoma is mediated by dysregulated lncRNA MALAT1 through modulation of tumor microenvironment

Cutaneous T-Cell Lymphoma (CTCL) is a rare non-Hodgkin lymphoma marked by migration of T-lymphocytes to the skin. It has many subtypes some of which are aggressive with documented metastasis. We investigated a possible role of lncRNA MALAT1 in CTCL cells because of its documented involvement in cancer metastasis. A screening of MALAT1 in CTCL patients revealed its elevated levels in the patients, compared to healthy individuals. For our investigation, we employed HH and H9 CTCL cells and silenced MALAT1 to understand the MALAT1 mediated functions. Such silencing of MALAT1 resulted in reversal of EMT and inhibition of cancer stem cell phenotype, along with reduced cell growth and proliferation. EMT reversal was established through increased E-cadherin and reduced N-cadherin while inhibition of cancer stem cell phenotype was evident through reduced Sox2 and Nanog. CTCL patients had higher circulating levels of IL-6, IL-8, IL-10, TGFβ, PGE2 and MMP7 which are factors released by tumor-associated macrophages in tumor microenvironment. MALAT1 sponged miR-124 as this tumor suppressive miRNA was de-repressed upon MALAT1 silencing. Moreover, downregulation of miR-124 attenuated MALAT1 silencing effects. Our study provides a rationale for further studies focused on an evaluation of MALAT1-miR-124 in CTCL progression.

[1]  Xuxia Tang,et al.  Long Noncoding RNA MALAT1 Promotes Laryngocarcinoma Development by Targeting miR-708-5p/BRD4 Axis to Regulate YAP1-Mediated Epithelial-Mesenchymal Transition , 2022, BioMed research international.

[2]  Wenxuan Xu,et al.  MALAT1-related signaling pathways in colorectal cancer , 2022, Cancer cell international.

[3]  Yuanyuan Chen,et al.  Novel Insights Into MALAT1 Function as a MicroRNA Sponge in NSCLC , 2021, Frontiers in Oncology.

[4]  Anuradha Dhanasekaran,et al.  LncRNA MALAT1 Promotes Tumor Angiogenesis by Regulating MicroRNA-150-5p/VEGFA Signaling in Osteosarcoma: In-Vitro and In-Vivo Analyses , 2021, Frontiers in Oncology.

[5]  Aamir Ahmad.  Epigenetic regulation of immunosuppressive tumor-associated macrophages through dysregulated microRNAs. , 2021, Seminars in cell & developmental biology.

[6]  Aamir Ahmad,et al.  Long non-coding RNAs Regulated NF-κB Signaling in Cancer Metastasis: Micromanaging by Not So Small Non-coding RNAs. , 2021, Seminars in cancer biology.

[7]  T. Liang,et al.  LncRNA MALAT1 Accelerates Cervical Carcinoma Proliferation by Suppressing miR-124 Expression in Cervical Tumor Cells , 2021, Journal of oncology.

[8]  Wen Xu,et al.  Molecular mechanism of the canonical oncogenic lncRNA MALAT1 in gastric cancer. , 2021, Current medicinal chemistry.

[9]  Qianmei Fu,et al.  CCL21 activation of the MALAT1/SRSF1/mTOR axis underpins the development of gastric carcinoma , 2021, Journal of translational medicine.

[10]  Subash C. Gupta,et al.  Diagnostic, prognostic, and therapeutic significance of long non-coding RNA MALAT1 in cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[11]  B. Zhu,et al.  Metabolic regulatory crosstalk between tumor microenvironment and tumor-associated macrophages , 2021, Theranostics.

[12]  Zunyi Wang,et al.  LncRNA MALAT1 promotes breast cancer progression by sponging miR101-3p to mediate mTOR/PKM2 signal transmission. , 2021, American journal of translational research.

[13]  Priya Mondal,et al.  Long non-coding RNAs in breast cancer metastasis , 2020, Non-coding RNA research.

[14]  Xiaomei Lu,et al.  TGF-β1-Induced Upregulation of MALAT1 Promotes Kazakh's Esophageal Squamous Cell Carcinoma Invasion by EMT , 2020, Journal of Cancer.

[15]  C. Lebbé,et al.  Epidemiology of Cutaneous T-Cell Lymphomas: A Systematic Review and Meta-Analysis of 16,953 Patients , 2020, Cancers.

[16]  Yanning Liu,et al.  lncRNA MALAT1 modulates cancer stem cell properties of liver cancer cells by regulating YAP1 expression via miR-375 sponging , 2020, Molecular medicine reports.

[17]  A. Valladares-Salgado,et al.  Altered levels of MALAT1 and H19 derived from serum or serum exosomes associated with type-2 diabetes , 2020, Non-coding RNA research.

[18]  Xingmei Wu,et al.  The Long Non-Coding RNA MALAT1 Enhances Ovarian Cancer Cell Stemness by Inhibiting YAP Translocation from Nucleus to Cytoplasm , 2020, Medical science monitor : international medical journal of experimental and clinical research.

[19]  Chenjing Zhu,et al.  The Oncogenic and Tumor Suppressive Functions of the Long Noncoding RNA MALAT1: An Emerging Controversy , 2020, Frontiers in Genetics.

[20]  Shih-Jung Liu,et al.  Resorbable Beads Provide Extended Release of Antifungal Medication: In Vitro and In Vivo Analyses , 2019, Pharmaceutics.

[21]  Chih-Hung Lee,et al.  CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma , 2019, In Vivo.

[22]  Li Ma,et al.  New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis , 2019, Cancers.

[23]  M. Sang,et al.  miR-124 regulates EMT based on ZEB2 target to inhibit invasion and metastasis in triple-negative breast cancer. , 2018, Pathology, research and practice.

[24]  Zhuchu Chen,et al.  MiR-101-3p inhibits EMT to attenuate proliferation and metastasis in glioblastoma by targeting TRIM44 , 2018, Journal of Neuro-Oncology.

[25]  F. Jiao,et al.  A novel feedback loop between high MALAT-1 and low miR-200c-3p promotes cell migration and invasion in pancreatic ductal adenocarcinoma and is predictive of poor prognosis , 2018, BMC Cancer.

[26]  M. Ellis,et al.  Long non-coding RNA MALAT1 suppresses breast cancer metastasis , 2018, Nature Genetics.

[27]  Fan Yang,et al.  Missing Links in Epithelial-Mesenchymal Transition: Long Non-Coding RNAs Enter the Arena , 2017, Cellular Physiology and Biochemistry.

[28]  Linda Moreau,et al.  Comprehensive analysis of cutaneous T‐cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy , 2017, Cancer.

[29]  Aamir Ahmad.  Non-coding RNAs: A tale of junk turning into treasure , 2016, Non-coding RNA research.

[30]  Merve Mutlu,et al.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance , 2016, Journal of Molecular Medicine.

[31]  Ö. Sahin,et al.  miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance , 2016, Journal of Molecular Medicine.

[32]  D. Fan,et al.  The epithelial-mesenchymal transition and cancer stem cells: functional and mechanistic links. , 2015, Current pharmaceutical design.

[33]  Yang Zhang,et al.  Tumor-associated macrophage-derived IL-6 and IL-8 enhance invasive activity of LoVo cells induced by PRL-3 in a KCNN4 channel-dependent manner , 2014, BMC Cancer.

[34]  L. Wilson,et al.  Age, race, sex, stage, and incidence of cutaneous lymphoma. , 2012, Clinical lymphoma, myeloma & leukemia.

[35]  Nicola Pimpinelli,et al.  Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). , 2007, Blood.

[36]  K. Mills,et al.  Suppression of Antitumor Immunity by IL-10 and TGF-β-Producing T Cells Infiltrating the Growing Tumor: Influence of Tumor Environment on the Induction of CD4+ and CD8+ Regulatory T Cells1 , 2006, The Journal of Immunology.